Oguzhanoglu 1999.

Methods	Single‐centre, open‐label, randomised, parallel study: fluoxetine versus amitriptyline No control for symptomatic/analgesic medications use
Participants	Country: Turkey Overall: N = 52; Sex: 6 M, 41 F (sex not reported for drop‐outs) Migraine group: N = 17; Sex: 3 M, 12 F (sex not reported for drop‐outs); mean age: 31 Diagnosis: migraine (N = 17), CTTH (N = 14) and ETTH (N = 21), all defined according to International Headache Society criteria (IHS 1988) Exclusion criteria: antidepressants use in the previous year, score > 17 Hamilton Depression Scale Recruitment: from November 1996 to September 1997, no other information
Interventions	N = 22 amitriptyline to a maximum of 50 mg/day N = 25 fluoxetine 20 mg/day Duration of active treatment: unclear
Outcomes	1. Headache frequency (number of days with headache/30 days) 2. Pain intensity (not defined) 3. Headache duration (not defined)
Notes	Overall, 5 drop‐outs (10%) for side effects (2 in the migraine group) Per protocol analysis No sample size calculation
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information
Allocation concealment (selection bias)	Unclear risk	No information
Blinding (performance bias and detection bias) All outcomes	High risk	Open label
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Moderate drop‐out rate (2/17, 11.7%), reasons reported
Selective reporting (reporting bias)	Unclear risk	No information
Other bias	Unclear risk	Financial support not reported